Holen Sie sich die Stockscreener-App
198.76
1.11%
-2.24
Handel nachbörslich:
198.56
-0.20
-0.10%
Schlusskurs vom Vortag:
$201.00
Offen:
$198.16
24-Stunden-Volumen:
375.63K
Relative Volume:
0.48
Marktkapitalisierung:
$4.18B
Einnahmen:
$1.77M
Nettoeinkommen (Verlust:
$-123.74M
KGV:
-21.68
EPS:
-9.17
Netto-Cashflow:
$-95.21M
1W Leistung:
+14.25%
1M Leistung:
+275.02%
6M Leistung:
+428.06%
1J Leistung:
+183.98%
1-Tages-Spanne:
$195.50
$201.99
1-Wochen-Bereich:
$174.55
$206.71
52-Wochen-Spanne:
$26.70
$206.71
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Firmenname
Praxis Precision Medicines Inc
Sektor
Branche
Telefon
617-300-8460
Adresse
99 HIGH STREET, 30TH FLOOR, BOSTON
Vergleichen Sie PRAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
198.76 | 5.00B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-08-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-24 | Eingeleitet | Needham | Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Buy |
| 2024-05-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-19 | Eingeleitet | Truist | Buy |
| 2022-06-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-26 | Eingeleitet | BofA Securities | Buy |
| 2021-04-26 | Eingeleitet | William Blair | Outperform |
| 2020-11-11 | Eingeleitet | Wedbush | Outperform |
| 2020-11-10 | Eingeleitet | Cowen | Outperform |
| 2020-11-10 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
Using Python tools to backtest Praxis Precision Medicines Inc. strategiesWeekly Risk Summary & Real-Time Chart Pattern Alerts - newser.com
Is Praxis Precision Medicines Inc. stock near bottom after declineJuly 2025 Trade Ideas & Fast Moving Stock Trade Plans - newser.com
How Praxis Precision Medicines Inc. stock valuations compare to rivalsTrade Analysis Summary & Long-Term Capital Growth Strategies - newser.com
Is a relief rally coming for Praxis Precision Medicines Inc. holdersJuly 2025 Momentum & Entry and Exit Point Strategies - newser.com
Can Praxis Precision Medicines Inc. stock deliver surprise earnings beatJuly 2025 Pullbacks & Detailed Earnings Play Strategies - newser.com
Published on: 2025-11-01 00:59:14 - newser.com
Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 1-Year HighHere's What Happened - MarketBeat
Praxis Precision Medicines stock hits 52-week high at $206.36 By Investing.com - Investing.com Australia
What institutional flow reveals about Praxis Precision Medicines Inc.Forecast Cut & Real-Time Market Trend Scan - newser.com
Does Praxis Precision Medicines Inc. qualify in momentum factor screening2025 Institutional Moves & High Yield Stock Recommendations - newser.com
Published on: 2025-10-31 03:19:21 - newser.com
What valuation multiples suggest for Praxis Precision Medicines Inc. stockDividend Hike & Proven Capital Preservation Tips - newser.com
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Praxis Precision Medicines stock hits 52-week high at $206.36 - Investing.com
Praxis Precision Medicines (PRAX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Published on: 2025-10-29 21:58:45 - newser.com
What’s Happening With Praxis Stock? - Trefis
Does Positive Phase 3 Data for Ulixacaltamide Transform the Outlook for Praxis Precision Medicines (PRAX)? - Sahm
Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Published on: 2025-10-29 03:41:05 - newser.com
Praxis Precision Medicines’ PRAX-562 Trial: A Potential Game-Changer for Epileptic Encephalopathies - TipRanks
Praxis Precision Medicines (PRAX) Price Target Increased by 153.57% to 258.64 - Nasdaq
Praxis Precision Medicines Signs New Sales Agreement - MSN
Praxis Precision Medicines, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Applying big data sentiment scoring on Praxis Precision Medicines Inc.Weekly Profit Analysis & Community Verified Watchlist Alerts - newser.com
Praxis Precision Medicines (PRAX): Evaluating Valuation After Positive Phase 3 Results for Essential Tremor Drug - Sahm
Published on: 2025-10-27 23:27:23 - fcp.pa.gov.br
How to use Fibonacci retracement on Praxis Precision Medicines Inc.Watch List & Trade Opportunity Analysis - newser.com
Praxis Precision Medicines Advances Elsunersen Trial for Pediatric Epileptic Encephalopathy - TipRanks
Praxis Precision Medicines Advances Phase 3 Trial for DEE Treatment - TipRanks
Praxis Precision Medicines Advances Phase 3 Study for Essential Tremor Treatment - TipRanks
Finanzdaten der Praxis Precision Medicines Inc-Aktie (PRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):